Neurocentria, Inc.
Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression, and Alzheimer’s disease. The company focuses on innovative therapies targeting fundamental neurological mechanisms, with a mission to improve patients' quality of life through science-backed, novel treatment options. Their approach involves a new class of therapies that promote synaptogenesis and enhance synaptic function, leveraging intracellular magnesium regulation as a key mechanism.
Industries
Nr. of Employees
small (1-50)
Neurocentria, Inc.
200 Pringle Ave., Ste. 325 Walnut Creek, CA, 94596
Patents
Methods of modifying neuronal function by changing intracellular magnesium levels
US-11278567-B2
View DetailsMethods of modifying neuronal function by changing intracellular magnesium levels
US-10617713-B2
View Details
Methods of modifying neuronal function by changing intracellular magnesium levels
US-11278567-B2
View DetailsMethods of modifying neuronal function by changing intracellular magnesium levels
US-10617713-B2
View DetailsProducts
Magnesium L‑threonate dietary supplement
Oral nutraceutical formulation of magnesium L‑threonate developed for supporting brain health in healthy adults; the formulation has received GRAS affirmation and is commercially marketed.
Magnesium L‑threonate dietary supplement
Oral nutraceutical formulation of magnesium L‑threonate developed for supporting brain health in healthy adults; the formulation has received GRAS affirmation and is commercially marketed.
Services
Design and execution of late-stage clinical trials and associated clinical operations for neuropsychiatric and neurodegenerative indications.
Design and execution of late-stage clinical trials and associated clinical operations for neuropsychiatric and neurodegenerative indications.
Expertise Areas
- CNS drug discovery
- Synaptic plasticity and translational neuroscience
- Preclinical efficacy testing and animal models
- Clinical trial design and execution (late-stage CNS trials)
Key Technologies
- Small-molecule CNS pharmacology
- Synaptic plasticity assays
- Preclinical animal models of cognition and neurodegeneration
- CSF and brain magnesium pharmacology assays